Amazon launches GLP-1 weight-loss programme via One Medical
Eli Lilly and Novo Nordisk shares fell on the news; Hims & Hers faces questions over lost upside potential
Briefing
- •Amazon is launching a comprehensive GLP-1 weight management programme through its One Medical unit, promising fast and convenient access to the medications.
- •The programme includes upfront GLP-1 medication costs, positioning Amazon as a direct, integrated provider rather than a referral channel.
- •Eli Lilly and Novo Nordisk shares fell in response, reflecting investor concern that Amazon's distribution scale could compress pricing power for branded GLP-1 drugs.
- •Hims & Hers, which built a business around compounded GLP-1 access, faces renewed questions about its competitive positioning now that Amazon has entered the space.
Why it matters
- →Amazon's integrated GLP-1 model, covering prescribing through One Medical and dispensing through Amazon Pharmacy, removes the pharmacy benefit manager and specialty pharmacy margin layers that Lilly and Novo currently rely on to maintain net pricing. If Amazon negotiates directly for volume at compressed net prices, the effective per-unit revenue for branded semaglutide and tirzepatide declines without a visible list price cut, making the margin compression harder to track and defend publicly.
- →Hims & Hers built its GLP-1 revenue base around compounded semaglutide access during the FDA shortage period. That window was already narrowing after the FDA's shortage delisting; Amazon's entry now eliminates the convenience and cost-access differentiation that was HIMS's residual competitive argument. Amazon's One Medical has physical exam infrastructure, which satisfies the prescribing requirement that compounders cannot replicate at scale, directly undercutting HIMS's telehealth positioning.
- →Amazon's move is structurally additive to the managed care and PBM pressure dynamic already visible in UnitedHealth's Q1 results. If Amazon captures GLP-1 prescribing and dispensing volume through One Medical and Amazon Pharmacy, PBMs lose adjudication fees and rebate capture on one of the highest-growth drug categories. CVS Health's Caremark and Express Scripts face direct volume displacement in a category that has been a key offset to declining generic dispensing margins.
Historical Context
- 2018
Amazon acquired PillPack for roughly $1 billion, signaling pharmacy ambitions. The market initially sold off pharmacy retailers; the actual margin impact materialized slowly. The One Medical acquisition in 2022 added the prescribing layer PillPack lacked, making the current GLP-1 programme the first time Amazon controls the full prescribe-dispense loop.
- 2022-2023
FDA shortage listings for semaglutide and tirzepatide opened the compounded GLP-1 market, which HIMS and other telehealth platforms exploited. FDA's subsequent shortage delisting in early 2025 began closing that window; Amazon's integrated programme now provides a branded alternative at scale that compounders cannot legally match.
Connected Events
UnitedHealth beats Q1 estimates by widest margin in five years, raises full-year outlook
UnitedHealth's Q1 beat and raised full-year outlook, driven by improving medical cost trends, signals managed care is stabilizing its cost base at the same moment Amazon is disrupting the specialty drug distribution chain that PBM-linked insurers depend on for GLP-1 rebate economics.
Trump executive order fast-tracks psychedelic drug research, lifting sector stocks
Trump's executive order fast-tracking psychedelic drug research reflects a broader administration posture of compressing regulatory pathways and encouraging non-traditional healthcare delivery, an environment that is permissive for Amazon's integrated clinical and dispensing model to expand beyond GLP-1s.
